Tejera-Muñoz Antonio, Marchant Vanessa, Tejedor-Santamaría Lucía, Opazo-Ríos Lucas, Lavoz Carolina, Gimeno-Longas María José, Aceña José L, Ruiz-Ortega Marta, Rodrigues-Díez Raúl R
Department of Endocrinology and Nutrition, General University Hospital Dr. Balmis of Alicante, Institute of Health and Biomedical Research of Alicante (ISABIAL), 03004 Alicante, Spain.
Health Science Faculty-HM Hospitals, Camilo José Cela University, 28036 Madrid, Spain.
Int J Mol Sci. 2025 Jun 7;26(12):5474. doi: 10.3390/ijms26125474.
Diabetic kidney disease (DKD) is a serious microvascular complication of diabetes mellitus and a leading cause of end-stage kidney disease. Despite its rising incidence, awareness and early detection of renal complications remain limited. Current research in DKD aims to identify non-invasive biomarkers for early diagnosis and to develop effective therapies that go beyond controlling risk factors, as few options are available to halt or reverse kidney inflammation and fibrosis. MicroRNAs (miRNAs), key regulators of gene expression, have emerged as promising candidates for both diagnosis and treatment in DKD. Among them, miR-802 has gained attention due to its role in modulating inflammatory, fibrotic, and metabolic pathways. Elevated levels of miR-802 correlate with renal inflammation and fibrosis in diabetic and obese models, highlighting its potential as both a diagnostic biomarker and a therapeutic target. This review focuses on the emerging evidence supporting the involvement of miR-802 in the pathogenesis of DKD and its potential role as a diagnostic and therapeutic tool. In addition, considering that miR-802 has also been implicated in other diseases, such as cancer, where it may act either as a tumor suppressor or an oncogene, these contrasting effects will also be discussed as part of the broader context to better understand the multifaceted biological roles of miR-802. This review emphasizes the need for further research to clarify the molecular mechanisms of miR-802 and to assess its potential for clinical translation in DKD.
糖尿病肾病(DKD)是糖尿病严重的微血管并发症,也是终末期肾病的主要病因。尽管其发病率不断上升,但对肾脏并发症的认知和早期检测仍然有限。目前DKD的研究旨在识别用于早期诊断的非侵入性生物标志物,并开发超越控制风险因素的有效治疗方法,因为几乎没有办法阻止或逆转肾脏炎症和纤维化。微小RNA(miRNA)作为基因表达的关键调节因子,已成为DKD诊断和治疗的有希望的候选者。其中,miR-802因其在调节炎症、纤维化和代谢途径中的作用而受到关注。在糖尿病和肥胖模型中,miR-802水平升高与肾脏炎症和纤维化相关,突出了其作为诊断生物标志物和治疗靶点的潜力。本综述重点关注支持miR-802参与DKD发病机制的新证据及其作为诊断和治疗工具的潜在作用。此外,鉴于miR-802也与其他疾病有关,如癌症,它在其中可能作为肿瘤抑制因子或癌基因起作用,这些相反的作用也将作为更广泛背景的一部分进行讨论,以更好地理解miR-802多方面的生物学作用。本综述强调需要进一步研究以阐明miR-802的分子机制,并评估其在DKD中临床转化的潜力。